Research
Hormonal
VLCKD is contraindicated in patients with Type 1 Diabetes, renal failure, liver failure, and certain cardiac conditions due to risks of euglycemic ketoacidosis, electrolyte imbalance, and metabolic stress.
Do not attempt this diet if you have Type 1 Diabetes, kidney or liver disease, or severe heart failure. These conditions make the metabolic shift of ketosis dangerous. Consult your doctor for safer alternatives.
StrongRefutesVERY_HIGH confidence
The absolute contraindications are represented by type 1 diabetes mellitus... kidney failure and moderate-to-severe chronic kidney disease, liver failure, hearth failure (NYHA III–IV)... use of sodium/glucose cotransporter 2 (SGLT2) inhibitors (risk for euglycemic diabetic ketoacidosis)...
Why this rating
Based on consensus guidelines (SIE, ADI) cited in the paper.
Source
The management of very low-calorie ketogenic diet in obesity outpatient clinic: a practical guide
Giovanna Muscogiuri et al. · Journal of Translational Medicine · 2019
DOI 10.1186/s12967-019-2104-z
narrative_reviewCited 177×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
- Very low-calorie ketogenic diets (VLCKD) induce rapid weight loss primarily through initial natriuresis and diuresis driven by decreased insulin and increased glucagon, followed by sustained loss due to severe caloric restriction and preserved lean mass.Good
- VLCKD preserves lean body mass better than starvation or standard very low-calorie diets due to high biological-value protein intake and ketone-mediated protein sparing.Good
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →